168 related articles for article (PubMed ID: 32586577)
21. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Patel K; Pagel JM
Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
[TBL] [Abstract][Full Text] [Related]
22. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Bartlett NL; Caimi PF; Chang JE; Chavez JC; Christian B; Fayad LE; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Kaminski MS; Kelsey CR; Khan N; Krivacic S; LaCasce AS; Mehta A; Nademanee A; Rabinovitch R; Reddy N; Reid E; Roberts KB; Smith SD; Snyder ED; Swinnen LJ; Vose JM; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2019 Jun; 17(6):650-661. PubMed ID: 31200358
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
24. Umbralisib: First Approval.
Dhillon S; Keam SJ
Drugs; 2021 May; 81(7):857-866. PubMed ID: 33797740
[TBL] [Abstract][Full Text] [Related]
25. New agents in follicular lymphoma.
Cheson BD
Best Pract Res Clin Haematol; 2011 Jun; 24(2):305-12. PubMed ID: 21658626
[TBL] [Abstract][Full Text] [Related]
26. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
27. An analysis of genetic targets for guiding clinical management of follicular lymphoma.
Alonso-Alonso R; Rodriguez M; Morillo D; Cordoba R; Piris MA
Expert Rev Hematol; 2020 Dec; 13(12):1361-1372. PubMed ID: 33176509
[No Abstract] [Full Text] [Related]
28. The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients.
Mozas P; Sorigué M; Rivas-Delgado A; Rivero A; Correa JG; Castillo C; Nadeu F; Bataller A; Giné E; Baumann T; Delgado J; Villamor N; Campo E; Magnano L; Sancho JM; López-Guillermo A
Eur J Haematol; 2021 Mar; 106(3):428-432. PubMed ID: 33247499
[No Abstract] [Full Text] [Related]
29. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.
Bruna R; Benedetti F; Boccomini C; Patti C; Barbui AM; Pulsoni A; Musso M; Liberati AM; Gini G; Castellino C; Rossini F; Ciceri F; Rota-Scalabrini D; Stelitano C; Di Raimondo F; Tucci A; Devizzi L; Zoli V; Zallio F; Narni F; Dondi A; Parvis G; Semenzato G; Lanza F; Perrone T; Angrilli F; Billio A; Gueli A; Mantoan B; Rambaldi A; Gianni AM; Corradini P; Passera R; Ladetto M; Tarella C
Haematologica; 2019 Nov; 104(11):2241-2248. PubMed ID: 31666344
[TBL] [Abstract][Full Text] [Related]
30. Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma.
Cohen JB; Kahl BS
Hematol Oncol Clin North Am; 2020 Aug; 34(4):663-672. PubMed ID: 32586572
[TBL] [Abstract][Full Text] [Related]
31. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.
Yuan J; Greiner TC; Fu K; Smith LM; Aoun P; Chan WC; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Weisenburger DD
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):488-497.e2. PubMed ID: 28842137
[TBL] [Abstract][Full Text] [Related]
32. Rituximab for follicular lymphoma.
Maloney DG
Curr Hematol Rep; 2003 Jan; 2(1):13-22. PubMed ID: 12901150
[TBL] [Abstract][Full Text] [Related]
33. Follicular lymphoma: evolving therapeutic strategies.
Kahl BS; Yang DT
Blood; 2016 Apr; 127(17):2055-63. PubMed ID: 26989204
[TBL] [Abstract][Full Text] [Related]
34. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
Choi Y; Diefenbach CS
Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
[TBL] [Abstract][Full Text] [Related]
35. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L
Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991
[TBL] [Abstract][Full Text] [Related]
36. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?
Fowler N
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):277-283. PubMed ID: 27913492
[TBL] [Abstract][Full Text] [Related]
37. [Standard therapy and research questions in follicular lymphoma].
Ishizawa K
Rinsho Ketsueki; 2012 Oct; 53(10):1624-33. PubMed ID: 23037735
[No Abstract] [Full Text] [Related]
38. Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma.
Wullenkord R; Friedrichs B; Erdmann T; Lenz G
Expert Rev Hematol; 2019 Dec; 12(12):1053-1062. PubMed ID: 31583927
[No Abstract] [Full Text] [Related]
39. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
[TBL] [Abstract][Full Text] [Related]
40. Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma.
De la Cruz Vicente F; Carrillo-Cruz E; Rodriguez MS; Marín Niebla A; Galiana ML; Gonzalez JF; Cuadrado IM; Campos JG; Tocino IE; Rios-Herranz E; Perez-Simón JA
Eur J Haematol; 2014 Dec; 93(6):469-75. PubMed ID: 24853381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
